These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 36039657)
21. A randomized, adaptive design, double-blind, 3-arm, parallel study assessing the pharmacokinetics and safety of AVT02, a high-concentration (100 mg/mL) Adalimumab biosimilar, in healthy adult subjects (ALVOPAD FIRST). Wynne C; Schwabe C; Lemech C; Stroissnig H; Dias R; Sobierska J; Guenzi E; Otto H; Sattar A; Kay R; Haliduola HN; Berti F Expert Opin Investig Drugs; 2022 Sep; 31(9):965-976. PubMed ID: 35107050 [TBL] [Abstract][Full Text] [Related]
22. HLX11, a Proposed Pertuzumab Biosimilar: Pharmacokinetics, Immunogenicity, and Safety Profiles Compared to Three Reference Biologic Products (US-, EU-, and CN-Approved Pertuzumab) Administered to Healthy Male Subjects. Yang J; Lin L; Long Q; Zhang Q; Sun G; Zhou L; Wang Q; Zhu J; Li F; Hu W BioDrugs; 2022 May; 36(3):393-409. PubMed ID: 35594017 [TBL] [Abstract][Full Text] [Related]
23. A Randomized Phase 1 Pharmacokinetic Study Comparing the Potential Biosimilar LRG201902 With Liraglutide (Victoza Mai G; Fan L; Li M; Zhang P; Gan C; Huang Q; Shentu J Front Pharmacol; 2020; 11():610880. PubMed ID: 33584289 [No Abstract] [Full Text] [Related]
24. A Randomised Controlled Trial Comparing the Pharmacokinetics and Tolerability of the Proposed Adalimumab Biosimilar MSB11022 Delivered via Autoinjector and Pre-filled Syringe in Healthy Subjects. Sabet A; Dickerson DS; Kunina EE; Buccarello AL; Monnet J Rheumatol Ther; 2022 Apr; 9(2):693-704. PubMed ID: 35262901 [TBL] [Abstract][Full Text] [Related]
25. GP2017: An Adalimumab Biosimilar. Heo YA BioDrugs; 2018 Dec; 32(6):635-638. PubMed ID: 30460599 [TBL] [Abstract][Full Text] [Related]
26. Pharmacokinetics, safety, tolerability, and immunogenicity of FKB238, a new biosimilar of bevacizumab, in healthy participants. Boyce M; Wilkes D; Kaito H; Takanuma M; Arai Y Int J Clin Pharmacol Ther; 2022 Jun; 60(6):280-290. PubMed ID: 35361328 [TBL] [Abstract][Full Text] [Related]
27. Comparison of the pharmacokinetics, safety, and immunogenicity of MSB11022, a biosimilar of adalimumab, with Humira(®) in healthy subjects. Hyland E; Mant T; Vlachos P; Attkins N; Ullmann M; Roy S; Wagner V Br J Clin Pharmacol; 2016 Oct; 82(4):983-93. PubMed ID: 27285856 [TBL] [Abstract][Full Text] [Related]
28. A phase I study comparing the biosimilarity of the pharmacokinetics and safety of recombinant humanized anti-vascular endothelial growth factor monoclonal antibody injection with Avastin Li H; Zhao X; Xie J; Zhu X; Su Y; He C; Ding J; Zhu M; Xu Y; Wang Y; Shan R; Liu B; Ding Y; Liu Y; Zhou H; Xie Y BMC Pharmacol Toxicol; 2023 May; 24(1):36. PubMed ID: 37245022 [TBL] [Abstract][Full Text] [Related]
29. A Randomized, Double-Blind, Parallel-Group, Phase 1 Clinical Trial Comparing the Pharmacokinetic, Safety, and Immunogenicity of the Biosimilar HS016 and the Originator Adalimumab in Chinese Healthy Male Subjects. Cao G; Yu J; Wu J; Wang J; Xue Y; Yang X; Zhang J Clin Pharmacol Drug Dev; 2021 Mar; 10(3):317-325. PubMed ID: 32463599 [TBL] [Abstract][Full Text] [Related]
30. Comparison of two biosimilarity studies of FKB327 with the adalimumab reference product: randomized phase 1 studies of single-blind, single-dose subcutaneous injection in healthy Japanese male participants. Yonemura T; Yazawa R; Haranaka M; Kawakami K; Takanuma M; Kanzo T; Stefanidis D; Arai Y BMC Pharmacol Toxicol; 2022 Jan; 23(1):6. PubMed ID: 34998419 [TBL] [Abstract][Full Text] [Related]
31. A phase 1, randomized, open-label, single-dose study to assess the relative bioavailability of a subcutaneous dose of FKB327 when administered using a prefilled syringe, a prefilled auto-injector, or a vial with disposable syringe in healthy subjects. Bush J; Kawakami K; Muniz R BMC Pharmacol Toxicol; 2019 Dec; 20(1):87. PubMed ID: 31888742 [TBL] [Abstract][Full Text] [Related]
32. A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin Wu J; Wu G; Xie L; Lv D; Xu C; Zhou H; Wu L; Zhang J; Shentu J Drugs R D; 2023 Jun; 23(2):175-183. PubMed ID: 37247166 [TBL] [Abstract][Full Text] [Related]
33. A randomized, double-blind, parallel-group phase I study comparing the pharmacokinetics, safety, and immunogenicity of LY01008, a candidate bevacizumab biosimilar, with its reference product Avastin® in healthy Chinese male subjects. Zhou R; Yang J; Liu Y; Zhang Q; Lu C; Tang K; Li X; Tang W; Gao E; Wu C; Dou C; Hu W Expert Opin Biol Ther; 2022 Feb; 22(2):263-269. PubMed ID: 34913787 [TBL] [Abstract][Full Text] [Related]
35. A Phase I, Randomized, Single-Dose Study to Evaluate the Biosimilarity of HOT-3010 to Adalimumab Among Healthy Chinese Male Subjects. Zhang H; Chen H; Li X; Wu M; Zhu X; Li C; Liu J; Wei H; Hu Y; Wang J; Yang Y; Zhu X; Ding Y Front Pharmacol; 2021; 12():646171. PubMed ID: 34122068 [No Abstract] [Full Text] [Related]
36. Single-Dose Pharmacokinetics, Pharmacodynamics and Immunogenicity, and Multiple-Dose Immunogenicity of INTP5 (Pegfilgrastim Biosimilar) Versus Reference Pegfilgrastim in Healthy Subjects. Singh I; Attrey A; Garg A; Patel R; Jose V Clin Drug Investig; 2021 Jan; 41(1):29-42. PubMed ID: 33236287 [TBL] [Abstract][Full Text] [Related]
37. Phase III Randomized Study of SB5, an Adalimumab Biosimilar, Versus Reference Adalimumab in Patients With Moderate-to-Severe Rheumatoid Arthritis. Weinblatt ME; Baranauskaite A; Niebrzydowski J; Dokoupilova E; Zielinska A; Jaworski J; Racewicz A; Pileckyte M; Jedrychowicz-Rosiak K; Cheong SY; Ghil J Arthritis Rheumatol; 2018 Jan; 70(1):40-48. PubMed ID: 28950421 [TBL] [Abstract][Full Text] [Related]
38. A randomized phase I comparative pharmacokinetic study comparing SB5 with reference adalimumab in healthy volunteers. Shin D; Lee Y; Kim H; Körnicke T; Fuhr R J Clin Pharm Ther; 2017 Dec; 42(6):672-678. PubMed ID: 28675520 [TBL] [Abstract][Full Text] [Related]
39. Pharmacokinetics and safety of IBI301 versus rituximab in patients with CD20 Jiang B; Ke X; Zhang Q; Xu W; Su H; Huang J; Zhang M; Wang H; Jin C; Zhu J; Liu L; Cai Z; Zhao X; Zhou J; Zhang X; Liu J; Zhou H; Yu J; Sun X; Qi J; Qiu L Sci Rep; 2020 Jul; 10(1):11676. PubMed ID: 32669656 [TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, parallel-group, single‑dose, pharmacokinetic bioequivalence study of INTP24 and bevacizumab in healthy adult men. Singh I; Patel R; Patel A; Jose V Cancer Chemother Pharmacol; 2020 Aug; 86(2):193-202. PubMed ID: 32627073 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]